A serum immunofixation blood test looks for an abnormal immunoglobulin produced by one clone of plasma cells or B cells. This protein may be called a monoclonal protein, M protein, paraprotein, or monoclonal immunoglobulin. Immunofixation is especially useful because it can confirm that a suspicious band is monoclonal and identify its heavy-chain class—such as IgG, IgA, or IgM—and whether it uses a kappa or lambda light chain. The test does not measure cancer directly and cannot distinguish monoclonal gammopathy of undetermined significance from multiple myeloma by itself. A faint band may represent a small, stable precursor condition, an immune response, a medication, or an early clonal disorder. Interpretation depends on serum protein electrophoresis, free light chains, blood counts, kidney function, calcium, symptoms, imaging, and sometimes bone marrow or tissue biopsy. This article explains how the method works, what common report wording means, and what usually happens after an abnormal result.
- Immunofixation identifies the type of monoclonal immunoglobulin but usually does not quantify its amount.
- A normal result does not exclude every plasma-cell disorder, particularly a light-chain or nonsecretory condition.
- A monoclonal band is a laboratory finding, not automatically multiple myeloma.
- Small or equivocal bands may need repeat testing and comparison with prior samples.
- Therapeutic monoclonal antibodies can sometimes imitate a patient’s M protein.
Table of Contents
- How serum immunofixation separates and identifies proteins
- Why the test is ordered
- Reading a normal, abnormal, or equivocal report
- What diseases can produce a monoclonal band
- The companion tests that complete the picture
- Limitations, small bands, and treatment interference
- What happens after a positive immunofixation
- Monitoring results and symptoms that need prompt care
How serum immunofixation separates and identifies proteins
Immunoglobulins are antibodies made by plasma cells. A complete antibody contains two identical heavy chains and two identical light chains. Heavy chains determine the class: IgG, IgA, IgM, IgD, or IgE. Light chains are either kappa or lambda. Normal immunity produces a diverse, polyclonal mixture made by many different cell families.
A clonal population produces copies of one immunoglobulin. Because those copies have the same size, electrical charge, heavy chain, and light chain, they migrate together in laboratory separation and form a restricted band. Immunofixation electrophoresis is designed to reveal and type that band.
The laboratory applies serum to several lanes on a gel or another separation medium. An electric field separates proteins according to their physical properties. Each lane is then exposed to an antiserum that recognizes a particular immunoglobulin component—commonly IgG, IgA, IgM, kappa, or lambda. The antibody-antibody complexes precipitate in place, and unbound proteins are washed away. A matching restricted band in one heavy-chain lane and one light-chain lane identifies the isotype, such as IgG-kappa.
Serum immunofixation is more sensitive for small monoclonal proteins than routine serum protein electrophoresis. SPEP displays the overall protein pattern and can estimate the size of a discrete M spike when it is measurable. Immunofixation provides identity. The two methods answer related but different questions.
A typical panel tests IgG, IgA, IgM, kappa, and lambda. Laboratories can add IgD or IgE antisera when a rare heavy-chain type is suspected. Some centers use immunosubtraction or mass spectrometry-based monoclonal protein testing instead of conventional gel immunofixation. The report should state the method because sensitivity and terminology differ.
The visual position of a band is also recorded. A patient’s established M protein tends to recur in the same migration region, so comparison with archived gels or prior reports can help distinguish it from a new oligoclonal band or drug signal. This comparison is particularly useful during treatment, when several small bands may coexist.
No special preparation is generally required. Blood is collected from a vein, allowed to clot, and serum is separated. Fasting is not usually necessary unless another simultaneous test requires it. Recent transfusion, immunoglobulin therapy, and monoclonal antibody drugs should be documented because they can alter the protein pattern.
Why the test is ordered
Immunofixation may be ordered after an abnormal total protein, globulin, SPEP, or free light-chain result. It may also be included from the start when clinical suspicion is high, because a small monoclonal protein can be missed or obscured on SPEP.
Reasons for testing include:
- unexplained anemia or other low blood counts;
- kidney impairment or protein in the urine without a clear cause;
- high calcium;
- persistent bone pain, fractures, or lytic lesions;
- recurrent infections or suppressed normal immunoglobulins;
- unexplained neuropathy;
- enlarged lymph nodes, liver, or spleen;
- hyperviscosity symptoms;
- cardiomyopathy, nephrotic syndrome, or other signs that raise concern for amyloidosis;
- purpura, cryoglobulinemia, or cold-antibody symptoms; and
- monitoring a previously identified monoclonal protein.
The test is also used to assess response in plasma-cell disorders. Under commonly used myeloma response criteria, a complete response includes negative serum and urine immunofixation along with other requirements. A protein may become too small to quantify by electrophoresis yet remain visible by immunofixation, which can correspond to a very good partial response rather than complete response.
Screening every healthy person with immunofixation is not generally recommended. Monoclonal gammopathy becomes more common with age, and discovering a tiny asymptomatic clone can lead to years of follow-up. Testing is most useful when the clinical or laboratory context would change management.
A clinician may order serum and urine immunofixation together in selected situations. Urine testing detects monoclonal free light chains that pass through the kidneys, historically called Bence Jones proteins. Modern serum free light-chain assays have reduced but not eliminated the role of urine studies. Urine remains important in suspected light-chain amyloidosis, some renal presentations, and formal response assessment.
Immunofixation should not be confused with quantitative immunoglobulin testing. An immunoglobulin panel reports how much IgG, IgA, and IgM is present but does not show whether an elevation is monoclonal. Conversely, immunofixation can identify a tiny clone even when total immunoglobulin concentrations remain within range.
Reading a normal, abnormal, or equivocal report
A normal report may say “no monoclonal protein detected,” “no evidence of monoclonal gammopathy,” or “polyclonal pattern.” A polyclonal pattern contains a diffuse mixture of heavy and light chains, as expected from many plasma-cell clones. It may be entirely normal or broadly increased because of inflammation, infection, liver disease, or autoimmunity.
An abnormal report often names the type:
- IgG-kappa monoclonal protein
- IgG-lambda monoclonal protein
- IgA-kappa monoclonal protein
- IgA-lambda monoclonal protein
- IgM-kappa monoclonal protein
- IgM-lambda monoclonal protein
- free kappa or free lambda light chain
- biclonal proteins, meaning two distinguishable monoclonal components
The heavy- and light-chain label does not identify the disease stage. IgG is the most common heavy-chain class in plasma-cell gammopathies, but the same isotype can occur in MGUS, smoldering myeloma, active myeloma, and monoclonal gammopathy of clinical significance. IgM more often points toward IgM MGUS or a lymphoplasmacytic lymphoma such as Waldenström macroglobulinemia, although exceptions occur.
“Faint,” “trace,” “small restricted band,” or “cannot exclude a monoclonal protein” signals limited certainty or low abundance. A tiny band may be clinically important in amyloidosis or renal disease, but it can also be transient after infection, transplantation, immune reconstitution, or treatment. The laboratory may recommend repeating the test or correlating with free light chains.
An oligoclonal pattern contains several small restricted bands rather than one dominant clone. It can appear during immune recovery, after stem-cell transplantation, following effective myeloma treatment, or with chronic immune stimulation. Oligoclonal bands do not necessarily represent relapse and should be compared with the original patient-specific M protein.
“Restricted kappa” or “restricted lambda” without a clear heavy chain may indicate a free light-chain monoclonal protein, a very small intact immunoglobulin, technical limitation, or an unusual heavy-chain disease. The free light-chain assay and sometimes repeat or expanded immunofixation help clarify it.
The report may mention a band in the beta region, where IgA proteins frequently migrate and can overlap normal transferrin or complement proteins. This overlap can make SPEP quantification difficult even when immunofixation clearly establishes monoclonality.
The term “positive” means a monoclonal or restricted component was detected; it does not mean the patient has cancer. The result must be placed into a diagnostic category using cell burden and organ impact.
What diseases can produce a monoclonal band
A monoclonal protein reflects an expanded clone of plasma cells or mature B cells. The spectrum ranges from common precursor states to malignant and organ-damaging disorders.
Monoclonal gammopathy of undetermined significance (MGUS) is the most frequent explanation. In non-IgM MGUS, the serum M protein is below the diagnostic threshold for smoldering myeloma, clonal marrow plasma cells are limited, and there are no myeloma-defining events or organ damage attributable to the clone. MGUS is not treated, but risk-based follow-up is recommended because a small proportion progresses over time.
Smoldering multiple myeloma has a higher M-protein or marrow plasma-cell burden than MGUS but lacks myeloma-defining events. It carries a greater progression risk and requires hematology assessment. Selected high-risk patients may be considered for early treatment within current specialist practice, but the immunofixation result itself does not determine that decision.
Active multiple myeloma is diagnosed when clonal plasma cells or a plasmacytoma occur with one or more myeloma-defining events. These include attributable hypercalcemia, kidney impairment, anemia, bone lesions, or validated biomarkers that predict near-inevitable organ damage. Immunofixation supports detection of the secreted protein but is not one of these findings by itself.
Waldenström macroglobulinemia and other B-cell lymphomas may secrete an IgM monoclonal protein. Symptoms can result from marrow infiltration, enlarged nodes or spleen, hyperviscosity, neuropathy, cryoglobulins, or antibody activity. Bone marrow morphology and immunophenotype distinguish these disorders from plasma-cell myeloma.
AL amyloidosis occurs when a small plasma-cell clone produces a misfolding light chain that deposits in tissues. The monoclonal protein may be faint, so serum immunofixation, urine immunofixation, and free light chains are commonly combined. Cardiac, kidney, nerve, liver, or gastrointestinal involvement determines urgency.
Monoclonal gammopathy of clinical significance describes a clone that is too small to meet criteria for myeloma or lymphoma but whose protein causes organ injury. Examples affect kidneys, nerves, skin, eyes, or the complement system. “Undetermined significance” is inappropriate when a causal organ disorder is established.
Solitary plasmacytoma, heavy-chain disease, POEMS syndrome, cryoglobulinemia, and cold agglutinin disease can also produce monoclonal findings. The phenotype guides targeted tests.
A biclonal result may represent two separate clones or two proteins related to one clone. It does not automatically imply a more aggressive condition. Follow-up tracks each component and the associated clinical diagnosis.
The companion tests that complete the picture
Immunofixation is rarely interpreted alone. A standard monoclonal protein evaluation combines methods because each catches a different part of the spectrum.
SPEP shows albumin and globulin fractions, reveals a measurable M spike, and indicates polyclonal background changes. It is less sensitive than immunofixation for very small proteins but better for quantification.
Serum free light chains measure unbound kappa and lambda chains and calculate a ratio. A markedly skewed kappa/lambda ratio supports clonality, especially in light-chain disease. Kidney impairment raises both light chains and changes the expected ratio, so renal-adjusted interpretation may be necessary.
Quantitative immunoglobulins show the absolute IgG, IgA, and IgM concentrations. A clonal protein may raise its own class while suppressing uninvolved immunoglobulins, a pattern called immunoparesis. Normal quantities do not exclude a small clone.
Urine protein electrophoresis and immunofixation assess monoclonal light-chain excretion and quantify 24-hour urinary M protein when needed. A random sample can be useful in some diagnostic contexts, but formal criteria may call for a timed collection.
Complete blood count, creatinine, calcium, albumin, and total protein look for anemia, kidney injury, hypercalcemia, and protein abnormalities. Lactate dehydrogenase and beta-2 microglobulin may be added after a malignancy is diagnosed for staging or prognosis rather than screening.
Bone marrow aspiration and biopsy determine the percentage and phenotype of clonal cells. Flow cytometry, chromosome analysis, fluorescence in situ hybridization, and molecular testing provide disease classification and risk information.
Imaging is selected according to the suspected disorder. Low-dose whole-body CT, PET/CT, or MRI may evaluate bone disease and plasmacytomas. Echocardiography, cardiac biomarkers, and tissue imaging may be needed when amyloidosis is suspected.
Tissue biopsy with Congo red staining and mass spectrometry typing may establish amyloid. Kidney biopsy may identify monoclonal immunoglobulin deposits or complement-related injury. Finding a serum band does not prove that it caused organ damage; tissue correlation can be decisive.
Limitations, small bands, and treatment interference
A negative serum immunofixation does not rule out all clonal plasma-cell disorders. Some clones secrete only a small amount of free light chain, some proteins are primarily found in urine, and fewer than one percent of myelomas are truly nonsecretory. Amyloid-producing clones can be tiny. High clinical suspicion warrants a full panel and, when appropriate, tissue or marrow evaluation.
Sensitivity varies with specimen quality, protein concentration, antisera, technique, and reader interpretation. A band near another serum protein may be hard to resolve. Repeat testing at a reference laboratory or use of a more sensitive mass spectrometry method can occasionally clarify an uncertain pattern.
Polyclonal background can obscure a small monoclonal protein. This occurs in chronic liver disease, infection, autoimmune inflammation, and after intravenous immunoglobulin. IVIG contains pooled donor immunoglobulins and may create transient bands or broad changes. The infusion date should accompany the laboratory request.
Therapeutic monoclonal antibodies are an increasingly important source of interference. Drugs such as daratumumab are immunoglobulins and can appear as a small band, often IgG-kappa, on SPEP and immunofixation. Without drug information, the band can be mistaken for residual disease and prevent a patient from being classified as being in complete response.
Laboratories use several strategies to address drug interference: a drug-specific immunofixation reflex assay, comparison with the original M-protein migration, mass spectrometry, or testing after sufficient time has passed. The oncology team should tell the laboratory which monoclonal antibody therapies the patient has received.
After successful treatment or stem-cell transplantation, new oligoclonal bands may appear that differ from the original clone. These can reflect immune reconstitution rather than progression. Precise documentation of the initial isotype and migration position helps distinguish the patterns.
A positive band can also be transient. Infection, autoimmune activation, transplantation, and some neurologic or inflammatory conditions may create short-lived restricted responses. Persistence on repeat testing and agreement with other clonal markers increase confidence.
Immunofixation is mainly qualitative. Phrases such as faint or prominent are not substitutes for an M-protein concentration. Treatment decisions and progression assessment use quantitative electrophoresis, free light chains, marrow findings, imaging, and clinical events.
What happens after a positive immunofixation
The first step is confirmation and classification, not immediate treatment. The clinician reviews the isotype, SPEP quantity, free light-chain ratio, urine findings, blood counts, calcium, kidney function, symptoms, and prior results. A hematology referral is common when a new monoclonal protein is confirmed.
History and examination look for bone pain, fractures, fatigue, infections, weight loss, neuropathy, edema, shortness of breath, bruising, enlarged nodes, liver or spleen enlargement, and hyperviscosity symptoms. The relevance of the isotype matters: IgM prompts a somewhat different evaluation from IgG or IgA, and a free-light-chain band raises concern for light-chain disease or amyloidosis.
Bone marrow biopsy and advanced imaging are not required for every low-risk MGUS presentation. Current risk-based approaches may defer them when the M protein is small, the free light-chain ratio is normal, the isotype is lower risk, and there are no concerning clinical or laboratory features. The hematologist determines whether that pathway fits.
Features that make a more extensive evaluation more likely include:
- a larger or rising M protein;
- abnormal free light-chain ratio;
- IgA, IgM, or light-chain-only isotype in the appropriate context;
- anemia, kidney impairment, high calcium, or bone symptoms;
- suppressed uninvolved immunoglobulins;
- unexplained neuropathy, cardiomyopathy, or proteinuria;
- constitutional symptoms or enlarged nodes; and
- concern for amyloidosis or monoclonal gammopathy of clinical significance.
A faint band may be repeated in several months, sooner if organ injury is suspected. Waiting is not appropriate when kidney function is declining, cardiac biomarkers are abnormal, or neurologic deficits are progressing, because a small clone can still cause serious damage.
The diagnosis may ultimately be no clonal disorder, transient band, MGUS, smoldering myeloma, active myeloma, lymphoplasmacytic lymphoma, another lymphoma, amyloidosis, or a clone-related organ disorder. Immunofixation initiates this branch point but does not finish it.
Monitoring results and symptoms that need prompt care
For an established monoclonal gammopathy, follow-up tracks the same protein over time. The schedule depends on diagnosis and risk. MGUS is often reassessed after an initial interval to confirm stability, then less or more frequently according to isotype, M-protein size, free light-chain ratio, age, comorbidities, and changes in health.
Monitoring may include SPEP, quantitative immunoglobulins, free light chains, complete blood count, creatinine, calcium, and symptom review. Immunofixation can confirm disappearance, persistence, or identity, but repeated qualitative testing alone cannot measure growth precisely.
A change in band intensity from one report to another can reflect technical variation. Clinicians rely on quantitative trends and use the same laboratory when practical. A small rise is usually verified before a major decision unless symptoms or organ findings are changing simultaneously.
Seek prompt medical evaluation for new persistent bone pain, a fracture after minimal trauma, marked fatigue, recurrent infections, reduced urine output, swelling, unexplained weight loss, night sweats, rapidly worsening numbness or weakness, or shortness of breath. These symptoms are not specific, but they can signal progression or protein-related organ injury.
Emergency assessment is appropriate for confusion, severe headache, sudden visual disturbance, uncontrolled bleeding, chest pain, severe breathlessness, fainting, or neurologic deficits—particularly with a known high IgM protein or hyperviscosity risk. Acute kidney failure, severe hypercalcemia symptoms, spinal cord compression, and sepsis also require urgent care.
A monoclonal band is best understood as a precise clue. Immunofixation names the protein so clinicians can choose the correct diagnostic pathway, compare future samples, and avoid mistaking a broad inflammatory pattern for a clone. Its greatest value comes from combining that identity with quantity, cell burden, and evidence of what the protein or clone is doing to the body.
References
- Protein Electrophoresis by Immunofixation Blood Test 2024
- Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance: A Review 2025 (Review)
- A review of clinical guidelines, laboratory recommendations and external quality assurance programs for monoclonal gammopathy testing 2023 (Review)
- IMWG Criteria for the Diagnosis of Multiple Myeloma 2026 (Diagnostic Criteria)
- IMWG Uniform Response Criteria for Myeloma Treatment 2026 (Response Criteria)
- Monoclonal Protein Study, Quantitative, Serum 2026 (Laboratory Test Catalog)
Disclaimer
This article offers general educational information and cannot determine whether a monoclonal protein is benign, malignant, or causing organ damage. Test methods and diagnostic thresholds vary, and results require interpretation by a qualified clinician with the full laboratory and clinical record. Seek urgent care for severe neurologic, visual, bleeding, breathing, kidney, or infection symptoms.
